ReviewClinical and translational medicine2026
Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives.
Review in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInducible CRISPR/Cas systems enable spatiotemporal control of genome editing in response to chemical, optical, biological, or physical stimuli. By restricting genome-editing activity to defined conditions, these systems may reduce off-target exposure and immune burden while improving tumor-selective control, making them attractive tools for precision oncology. MAIN BODY: This review summarizes the molecular mechanisms, design principles, and current applications of inducible CRISPR/Cas systems in cancer research and therapy. These platforms are classified into chemically inducible, optogenetic, tumor microenvironment-responsive, physically triggered, and logic-gated systems. Regulatory strategies are discussed at multiple levels, including transcriptional control, post-translational regulation, guide RNA engineering, and stimulus-responsive delivery. Key applications include functional genomic screening, cancer modeling, therapeutic gene editing, immunotherapy enhancement, and combinatorial treatment strategies. We also examine current delivery approaches, including viral vectors, lipid nanoparticles, stimulus-responsive nanocarriers, and biomimetic platforms.
conclusionInducible CRISPR/Cas systems represent a promising platform for next-generation precision cancer therapy. However, substantial optimization and rigorous preclinical validation remain necessary to address challenges related to leaky expression, induction efficiency, tissue penetration, immunogenicity, and long-term safety before clinical translation can be realized. KEY POINTS: Inducible CRISPR/Cas systems enable conditional genome editing in precision oncology. Chemical, optical, TME-responsive, physical, and logic-gated systems offer distinct control features. Delivery, leakiness, immunogenicity, and safety remain key translational barriers. Ex vivo immune-cell engineering and locoregional delivery may offer nearer-term clinical routes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.